Merck Preps for End of Keytruda Exclusivity with $6.7B Deal for Leukemia Treatment
Corroborated by 1 source from 1 publisher
globalhealth1d ago
TL;DR
According to finance.yahoo.com, one executive’s patent cliff is another executive’s lucrative exit.
Corroborated by 1 source from 1 publisher
According to finance.yahoo.com, one executive’s patent cliff is another executive’s lucrative exit.